In November 2015, the Board at UNITAID approved the expansion of MPP’s mandate to cover hepatitis C and tuberculosis.
Hepatitis C is a liver disease caused by the Hepatitis C virus (HCV). According to WHO, approximately 72% of the up to 71 million people suffering from hepatitis C live in low- and middle-income countries.
New direct-acting antivirals (DAA) that are effective across all major HCV strains can cure millions. Approximately 95% of people infected with HCV worldwide are not receiving treatment.
To date, the MPP has signed agreements for two hepatitis C direct-acting antivirals. The foundation is working with 10 generic partners to speed development and distribution of new HCV treatments that can eliminate the virus in a short course of oral therapy in regions with a high HCV burden.